Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Serine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.67 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 2/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serine SCHEMBL418635 | 1.00 | PTGS1 (0.67) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 | |
| Serine SCHEMBL16058500 | 1.00 | PTGS1 (0.67) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 | |
| Serine SCHEMBL15417923 | 0.93 | PTGS1 (0.57) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 | |
| Serine SCHEMBL1162414 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GSRGRM8 | |
| Cysteine SCHEMBL1268415 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 | |
| Serine SCHEMBL1162408 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GSRGRM8 | |
| Cysteine SCHEMBL3320713 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 | |
| Serine SCHEMBL17113864 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GSRGRM8 | |
| Serine SCHEMBL17113867 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GSRGRM8 | |
| Cysteine SCHEMBL3320717 | 0.91 | PTGS1 (0.80) | PTGS1SLC7A11SLC1A1GLRA1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236510-B2 | Protein showing enhanced expression in cancer cells | AGENSYS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100291126-A1 | PROTEIN SHOWING ENHANCED EXPRESSION IN CANCER CELLS | AGENSYS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7795391-B2 | Protein showing enhanced expression in cancer cells | AGENSYS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7361338-B2 | Methods to inhibit growth of prostate cancer cells | AGENSYS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070270575-A1 | PROTEIN SHOWING ENHANCED EXPRESSION IN CANCER CELLS | AGENSYS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070061901-A9 | METHODS TO INHIBIT GROWTH OF PROSTATE CANCER CELLS | JAKOBOVITS AYA | 2007-03-15 | — | — | US | disclosed |
| US-20030213004-A1 | Nucleic acids and corresponding proteins entitled 101P3A11 or PHOR-1 useful in treatment and detection of cancer | AGENSYS, INC. | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291126-A1 | PROTEIN SHOWING ENHANCED EXPRESSION IN CANCER CELLS | TSG101, BCAP31, TFIP11 | PTGS1 3780/4885SLC7A11 3432/4885SLC1A1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.